Sugi Predict

Sugi Predict / Compounds / SCHEMBL2952230

SCHEMBL2952230

SCHEMBL2952230

CON(C)C(=O)c1sc2c(ccc(=O)n2-c2ccc(N(C)C)cc2)c1Nc1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 6/20 0.37
▸ ADORA2B P29275 1/20 0.36
▸ MAPK8 P45983 1/20 0.36
▸ CSF1R P07333 1/20 0.36
▸ LRP6 O75581 1/20 0.35
▸ MAPT P10636 4/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ TP53 P04637 2/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ THRB P10828 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ PMM2 O15305 1/20 0.33
▸ MPI P34949 1/20 0.33
▸ PHOSPHO1 Q8TCT1 1/20 0.33
▸ USP2 O75604 1/20 0.33
▸ TLR9 Q9NR96 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ TRPM8 Q7Z2W7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2949462 0.93 ADORA2B (0.38) ADORA2BMAPK8CSF1RMAPTTP53
Ammonia Solution, Strong SCHEMBL2956206 0.88 CSF1R (0.38) KDM1AMAPK8CSF1RMAPTMEN1
SCHEMBL2957153 0.86 MEN1 (0.46) CSF1RMAPTMEN1KMT2ARAB9A
SCHEMBL2950110 0.83 TERT (0.37) CSF1RMAPTTP53RAB9ATLR9
SCHEMBL2950157 0.82 CXCR2 (0.40) MAPK8MAPTMEN1KMT2ATP53
SCHEMBL2956215 0.79 PARP1 (0.42) MAPTMEN1KMT2ALMNAPOLB
SCHEMBL2954144 0.79 ALDH1A1 (0.44) ADORA2BMEN1KMT2ATP53RAB9A
SCHEMBL2947325 0.78 ADORA2B (0.37) ADORA2BMAPK8MAPTMEN1KMT2A
SCHEMBL2950153 0.78 BUB1 (0.36) MEN1KMT2APOLB
SCHEMBL2958436 0.78 KMT2A (0.41) CSF1RMAPTMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 — — US claimed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 — — US claimed
US-7763729-B2 Bicyclic heteroaromatic derivatives UCB PHARMA S.A. (BE) 2010-07-27 — — US disclosed
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives CELLTECH R&D LIMITED (GB) 2009-02-12 — — US disclosed
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 — — US disclosed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors MAPK1, CNKSR1, ALK KDM1A 459/4885ADORA2B 595/4885MAPK8 23/4885
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives MAPK1, CNKSR1, CBR1 KDM1A 369/4885ADORA2B 585/4885MAPK8 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.